UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Gastroenterology (New York, N.Y. 1943), 2016-06, Vol.150 (7), p.1568-1578

2016

Volltextzugriff (PDF)

P619 Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S396-S397

2017

Volltextzugriff (PDF)

P389 Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn's disease after ileal resection

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S275-S275

2017

Volltextzugriff (PDF)

P192 Heartburn in Crohn's disease is associated with increased disease activity, poor sleep quality and prior ileocecectomy

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S173-S174

2017

Volltextzugriff (PDF)

P468 Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology index

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S317-S317

2017

Volltextzugriff (PDF)

OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S6-S7

2017

Volltextzugriff (PDF)

DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s disease: a GEMINI 2 post hoc analysis

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S36-S38

2017

Volltextzugriff (PDF)

P410 Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S285-S286

2017

Volltextzugriff (PDF)

P558 The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S364-S365

2017

Volltextzugriff (PDF)

P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S315-S317

2017

Volltextzugriff (PDF)

P349 The effect of ulcerative colitis (UC) remission status after 8 weeks of induction therapy with MMX® mesalazine on long-term maintenance therapy outcomes (MOMENTUM Study): induction phase results

Journal of Crohn's and colitis, 2013-02, Vol.7, p.S149-S149

2013

Volltextzugriff (PDF)

P151 Recommendations for creating a high quality endoscopy report for inflammatory bowel disease patients: results from a RAND-appropriateness panel

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S125-S125

2014

Volltextzugriff (PDF)

P038 - Adalimumab sustains remission and quality-of-life improvements in anti-TNF-naive patients with Crohn's disease: 3-year data from CHARM

Journal of Crohn's and colitis, 2009-02, Vol.3 (1), p.S26

2009

Volltextzugriff (PDF)

Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis

Gut, 2004-04, Vol.53 (4), p.A119

2004

Volltextzugriff (PDF)

P008 - Adalimumab sustains quality-of-life improvements in patients with Crohn's disease: 3-year data from CHARM

Journal of Crohn's and colitis, 2009-02, Vol.3 (1), p.S14

2009

Volltextzugriff (PDF)

Confronting Health Misinformation Surrounding COVID-19 Vaccines in the State of Florida

Journal of general internal medicine : JGIM, 2024-06, Vol.39 (8), p.1488-1491

2024

Volltextzugriff (PDF)

Emricasan (IDN-6556) Orally for Three Months in Patients with Cirrhosis and Meld Scores 11–18 Improves Clinical Parameters of Cirrhosis in Patients with Baseline Meld Score ≥ 15

Journal of hepatology, 2016, Vol.64 (2), p.S210-S210

2016

Volltextzugriff (PDF)

A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e‐Delphi process and consensus meeting

British journal of dermatology (1951), 2022-11, Vol.187 (5), p.730-742

2022

Volltextzugriff (PDF)

Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project)

Journal of the European Academy of Dermatology and Venereology, 2021-09, Vol.35 (9), p.1888-1895

2021

Volltextzugriff (PDF)

Automated survival prediction in metastatic cancer patients using high-dimensional electronic medical record data

Annals of oncology, 2018-10, Vol.29, p.viii548-viii548

2018

Volltextzugriff (PDF)

Rosina – Rosetta Orbiter Spectrometer for Ion and Neutral Analysis

Space science reviews, 2007-02, Vol.128 (1-4), p.745-801

2007

Volltextzugriff (PDF)

LB05 - Emricasan (IDN-6556) Orally for Three Months in Patients with Cirrhosis and Meld Scores 11–18 Improves Clinical Parameters of Cirrhosis in Patients with Baseline Meld Score ≥ 15

Journal of hepatology, 2016, Vol.64 (2), p.S210-S210

2016

Volltextzugriff (PDF)

Regulation of Nicotinic Acetylcholine Receptor Phosphorylation in Rat Myotubes by Forskolin and cAMP

Proceedings of the National Academy of Sciences - PNAS, 1987-09, Vol.84 (18), p.6591-6595

1987

Volltextzugriff (PDF)

THE MOLECULAR BASIS OF REOVIRUS VIRULENCE

Animal Virus Genetics, 1980, p.663-671

1980

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)
Buchkapitel
(1)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(6)
Humans
(4)
Life Sciences & Biomedicine
(4)
Treatment Outcome
(3)
Delphi Technique
(2)
Dermatology
(2)
Gastroenterology And Hepatology
(2)
Original
(2)
Outcome Assessment, Health Care
(2)
Research Design
(2)
550201 - Biochemistry- Tracer Techniques
(1)
Acetylcholine
(1)
Adult
(1)
Amines
(1)
Amino Acids
(1)
Ammonium Compounds
(1)
Amp
(1)
Animals
(1)
Anti-Tnf
(1)
Astronomy & Astrophysics
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

P619 Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience

P389 Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn's disease after ileal resection

P192 Heartburn in Crohn's disease is associated with increased disease activity, poor sleep quality and prior ileocecectomy

P468 Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology index

OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study

DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s disease: a GEMINI 2 post hoc analysis

P410 Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC

P558 The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis

P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis

P349 The effect of ulcerative colitis (UC) remission status after 8 weeks of induction therapy with MMX® mesalazine on long-term maintenance therapy outcomes (MOMENTUM Study): induction phase results

P151 Recommendations for creating a high quality endoscopy report for inflammatory bowel disease patients: results from a RAND-appropriateness panel

P038 - Adalimumab sustains remission and quality-of-life improvements in anti-TNF-naive patients with Crohn's disease: 3-year data from CHARM

Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis

P008 - Adalimumab sustains quality-of-life improvements in patients with Crohn's disease: 3-year data from CHARM

Confronting Health Misinformation Surrounding COVID-19 Vaccines in the State of Florida

Emricasan (IDN-6556) Orally for Three Months in Patients with Cirrhosis and Meld Scores 11–18 Improves Clinical Parameters of Cirrhosis in Patients with Baseline Meld Score ≥ 15

A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e‐Delphi process and consensus meeting

Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project)

Automated survival prediction in metastatic cancer patients using high-dimensional electronic medical record data

Rosina – Rosetta Orbiter Spectrometer for Ion and Neutral Analysis

LB05 - Emricasan (IDN-6556) Orally for Three Months in Patients with Cirrhosis and Meld Scores 11–18 Improves Clinical Parameters of Cirrhosis in Patients with Baseline Meld Score ≥ 15

Regulation of Nicotinic Acetylcholine Receptor Phosphorylation in Rat Myotubes by Forskolin and cAMP

THE MOLECULAR BASIS OF REOVIRUS VIRULENCE

Suchergebnisse filtern